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Abstract
Background: Unintended pregnancies have been shown to be associated with high costs for the healthcare
system, among other adverse impacts, but could still account for up to 51 % of pregnancies in the US.
Improvements in contraception among women are needed. Long acting reversible contraceptives (LARCs),
which have proved their safety and efficacy, have been found to significantly decrease the risk of unintended
pregnancy. Yet they are still marginally employed. This study aims at investigating the evolution of LARC use
over 15 years and at assessing the impact of the introduction of newer LARCs on LARC use relative to all
contraceptive use.
Methods: This retrospective study identified women with LARC or short acting reversible contraceptive (SARC)
claims from a US insurance claims database (01/1999-03/2014). Yearly proportions of LARC users relative to all
contraceptive users were reported. Generalized estimating equation models were used to assess the impact of
user characteristics, such as age group (15–17, 18–24, 25–34, and 35–44), and of time periods related to the
introduction of new LARCs (01/2001: Mirena, 07/2006: Implanon, 01/2013: Skyla) on LARC use.
Results: A total of 1,040,978 women were selected. LARC use increased yearly from 0.6 % (1999) to 16.6 % (2013)
among contraceptive users. Time periods associated with the introduction of a newer LARC were significant predictors
of LARC use; women in 2006-2012 and 2013-2014 were respectively 3.7-fold (95 % CI:3.57–3.74) and 6.6-fold (95 %
CI:6.43–6.80) more likely to use LARCs over SARCs relative to women in 2001-2006. The increase in LARC use was
especially pronounced in young women. Compared to women aged 18–24 in 2001-2006, women aged 18–24 in
2006-2012 and 2013-2014 were respectively 6.4-fold (95 % CI:5.91–6.86) and 14.7-fold (95 % CI:13.59–15.89) more
likely to use LARCs over SARCs.
Conclusions: This broadly representative commercial claim-based study showed that the proportion of privately
insured women of childbearing age using LARCs increased over time and that the introduction of newer LARCs
corresponded with significant increases in overall LARC use. Future research is needed to assess LARC use
in uninsured or publicly-insured populations.
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Background
About half of the pregnancies in the United States (US)
are currently unintended [1, 2]. Unintended pregnancies
have been shown to have adverse social, economic, and
health outcomes for the mother, and for the child in
cases where the pregnancy turned into live birth [3].
Furthermore, their burden on the healthcare system
could be as high as $4.5 billion [4]. Decreasing the rate
of unintended pregnancies has therefore become a na-
tional public health goal [5]. In the US, according to a
2009 study, it was estimated that 43 % of unintended
pregnancies were due to inconsistent contraceptive use
[6]. Hence long acting reversible contraception (LARC)
methods, which solve issues related to adherence and
incorrect use, could significantly help in reducing unin-
tended pregnancies and their associated burdens [7, 8].
Despite the above, LARC methods are still largely
under-utilized among women [9–12]. Notably, in an
analysis of national surveys, Darroch et al. [12] reported
that the proportion of women using LARC methods in-
creased between 2003 and 2012 in developing countries
(from 6 to 9 %) but that it remained stable at 4 % in
higher income countries. Furthermore, recent studies
of the US National Survey of Family Growth (NSFG)
have reported an increase in the use of LARC among
women 15–44 years old from 2002 to the 2011–2013
time period [9, 11].
The main reasons identified for under-utilization of
LARC methods have been misconceptions about LARC
(such as safety concerns and non-eligibility of nulliparous
women) at the user and provider levels, over-estimation of
the efficiency of other contraceptive methods and the
ability of users to optimally use them, and perceived
higher costs [13]. With regards to higher costs, insur-
ance providers play an important role in determining
the consumer costs attributable to LARC use. It has
been demonstrated that women with low out-of-pocket
costs had a higher likelihood of choosing LARC com-
pared to women with high out-of-pocket costs [14],
and that providing complete insurance for LARC would
increase its use [13].
Most of these barriers can be addressed through im-
proved education of women and providers on LARC
and contraception in general [13]. By raising awareness,
providing opportunities to discuss the benefits and suit-
ability of LARC methods, and fulfilling women’s unmet
contraceptive needs by broadening the range of devices
and their duration, it can be assumed that the arrival
on the market of new LARC methods could contribute
to this effort.
The purpose of this study was to describe the evolu-
tion of LARC use over the period 1999–2014 and to
assess through the same time period the impact of
introducing new LARC methods on LARC use relative
to all contraceptive users in a large population of pri-
vately insured women using contraceptives.
Methods
Data source
This analysis was conducted using healthcare commercial
claims from the Optum Health Reporting and Insights
database encompassing the time period between January
1999 and March 2014. This database includes administra-
tive claims for over 18.5 million privately insured individ-
uals (17.1 million under age 65) covered by 84 self-insured
Fortune 500 companies with locations in all areas of the
United States. It contains eligibility information, some
demographic characteristics such as gender, region, and
salary for employees, along with complete medical and
pharmaceutical claims for all of the 84 companies’ benefi-
ciaries (i.e., employees, spouses, dependents, and retirees)
nationwide. The data are de-identified and comply with
the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 to preserve patient anonymity and
confidentiality.
Study design and patient selection
A retrospective longitudinal observational study design
was used. Women aged 15 to 44 years old at the time of
their SARC or LARC claim were selected. The study
period spanning from January 1999 through March 2014
was broken down into six and 12 month intervals for
the evaluation of the study endpoints. Some of the
analyses conducted required women having at least
12 months of continuous health plan eligibility before a
LARC or SARC claim. The Statistical Analysis Section
describes the analyses for which this selection criterion
was applied.
Study endpoints
The study endpoints were the use of SARC or LARC in
a given semester (semesters are herein defined as half-
years, running either from January 1 of a given year up
until June 30 of the same year, or from July 1 of a year
up until December 31 of the same year) or in a given
year. Women were classified as SARC users in a semes-
ter if they had at least 60 days of supply of SARC in that
semester, unless they initiated a LARC episode in the
same semester, in which case they were classified as
LARC users. LARC episodes were defined as the period
starting with a claim for a LARC device and ending
with the earliest of a removal, a pregnancy, an abortion,
the use of another contraceptive (SARC with more than
60 days of supply in the semester or permanent
sterilization), up to 5 years (Mirena users), up to 3 years
(Implanon/Nexplanon and Skyla users), up to 10 years
(ParaGard users), a procedure that led to sterilization
(i.e., hysterectomy, oophorectomy, salpingectomy), end
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of age eligibility criterion, end of health plan eligibility,
or the end of the data. Women were classified as LARC
users in a given semester if that semester overlapped a
LARC episode, unless the episode ended with SARC
use, in which case they were classified as SARC users.
For the assessment of the evolution of the proportion
of LARC users over time, LARC and SARC use was
evaluated yearly using the same definition.
A sensitivity analysis was also conducted using a 30 days
of supply threshold to identify SARC users (instead of
60 days of supply).
Statistical analysis
Baseline characteristics
Descriptive statistics were used to summarize the patient
characteristics assessed during the baseline periods for the
population having at least 12 months of continuous health
plan eligibility before a LARC or SARC claim. Mean,
standard deviation, and median were reported for descrip-
tive statistics of continuous variables, and absolute and
relative frequency counts were reported for categorical
variables.
Evolution of the proportion of LARC users over time
The proportion of women using LARC over women
using LARC or SARC was reported on a yearly basis
during the period 1999–2013. Proportions of LARC over
LARC and SARC use were reported each year by age
category (i.e., 15–17 years, 18–24 years, 25–34 years,
and 35–44 years). Statistical significance between con-
secutive years was assessed using a Pearson chi-squared
test. Of note, this analysis was conducted on a larger
sample size because it did not require a population
having at least 12 months of continuous health plan
eligibility for the assessment of characteristics prior to
the use of a SARC or LARC.
Predictors of LARC use over time
Generalized estimating equations (GEE) with logit link
for binary outcomes and adjusting for repeated meas-
urement every semester in patients who had at least
12 months of continuous eligibility before a SARC or
LARC claim were conducted to obtain odds ratios
(ORs) and 95 % confidence intervals (CIs). The GEE
approach was chosen to account for the longitudinal
and correlated nature of repeated semi-annual mea-
surements, particularly relevant in the case of LARCs
that lasted from 6 semesters for the shortest duration
devices (Implanon, Nexplanon and Skyla) up to 20 for
the longest (ParaGard). Patient characteristics evaluated
during the previous semester and used as predictors were
age group, region, insurance plan type, medical comorbid-
ities, nulliparous status, and gynecologic history. Dichot-
omous variables identifying the time periods associated
with the introduction of newer LARC methods (i.e.,
1999Q1-2000Q4, 2001Q1-2006Q2, 2006Q3-2012Q4,
and 2013Q1-2014Q1) were also used as predictors in
order to identify the impact of the introduction of
newer LARC methods (i.e., Mirena in 2001, Implanon/
Nexplanon in 2006, and Skyla in 2013) on LARC use.
Because the information on the type of industry and on
wages is only available for the primary plan holders
(i.e., employees) in the Optum Health Reporting and
Insights database, a sensitivity analysis was also conducted
on the subset of women employees to allow for the use of
the industry of employment and wages to be added as
covariates in the GEE model.
Finally, a GEE including interaction terms between age
groups (i.e., 15–17 years, 18–24 years, 25–34 years, and
35–44 years) and the time periods related to introduc-
tion of new LARCs were conducted to identify the
evolution in LARC use after introduction of new LARC
methods among the different age groups.
Results
Population baseline characteristics
A total of 1,040,978 women were identified to assess the
evolution of proportion of LARC use over time (Fig. 1),
while 732,430 women were selected for analyses that
used information collected prior to contraceptive claims
(12 months of continuous health plan eligibility before a
LARC or SARC claim).
Table 1 presents the characteristics of the latter popula-
tion at the time of a first SARC or LARC claim preceded
with more than 12 months of continuous eligibility, in
each period corresponding to the introduction of a newer
LARC method (i.e., 1999Q1-2000Q4, 2001Q1-2006Q2,
2006Q3-2012Q4, and 2013Q1-2014Q1). Across periods,
women opting for LARC were on average older by a few
years than those choosing SARC (32.5 vs 30.0 for women
in 1999–2000, 32.8 vs 28.8 in 2001–2006, 31.4 vs 27.4 in
2006–2012, and 30.3 vs 27.2 in 2013–2014). Also, a large
majority of women using LARC already had children
(as per the number of dependents identified under the
same insurance plan). However, the proportion of nul-
liparous LARC users increased since 2001 (14.2 % in
2001–2006, 29.2 % in 2006–2012, and 44.6 % in 2013–
2014). Moreover, the plan type increased over time in
the proportion of women covered by a point of service
(POS) plan (from ~35 % in 1999–2000 to ~63 % in 2013–
2014) and decreased in the proportion of women covered
by a preferred provider organization (PPO) plan (from
~34 % in 1999–2000 to ~15 % in 2013–2014).
Evolution of the proportion of LARC users over time
Figure 2 shows the evolution of the proportion of women
using LARC among women using LARC or SARC over
the time period encompassing 1999–2013. The proportion
Law et al. Reproductive Health  (2016) 13:96 Page 3 of 12
increased consistently from 0.61 % in 1999 up to 16.58 %
in 2013, and the difference in proportions compared to
the previous year was statistically significant for each year
after 2001. The figure also shows a majority of women
were 25–44 years old, and an acceleration in adoption of
LARC methods among younger women, particularly in
the group 18–24.
In the sensitivity analysis using a 30 days of supply
threshold to identify SARC users, the results remained
consistent (data not shown).
Predictors of LARC use over time
Table 2 displays the estimated odds of using LARC
among the population who used LARC or SARC from
1999 through 2014 and among the subset of women
employees. Time periods related to the introduction of
newer LARC methods were significant predictors of
LARC use, with women before 2001 being 0.28-fold
(95 % CI: 0.24-0.33) less likely to use LARC than
women in the period 2001–2006, women in the period
2006–2012 being 3.66-fold (95 % CI: 3.57-3.74) more
likely to use LARC than women in the period 2001–2006,
and women in the period 2013–2014 being 6.61-fold
(95 % CI: 6.43-6.80) more likely to use LARC than women
in 2001–2006.
Age group was another significant predictor of LARC
use. Compared to women aged 18–24 years, women
aged 15–17 years were 0.55-fold (95 % CI: 0.53-0.58) less
likely to use LARC, women aged 25–34 years were 1.03-
fold (95 % CI: 1.00-1.05) more likely to use LARC, and
women aged 35–44 were 1.21-fold (95 % CI: 1.18-1.24)
more likely to use LARC.
Regarding clinical factors, women with venous
thromboembolism (VTE) were 13.50-fold (95 % CI: 6.82-
26.72) more likely to use LARC compared to women
without VTE. All other comorbidities (i.e., systemic lupus
erythematous, epilepsy, hypertension, obesity, asthma,
diabetes, rheumatoid arthritis, and hypothyroidism),
except inflammatory bowel disease, were associated with a
higher likelihood of LARC use. Parous women were 2.29-
fold (95 % CI: 2.24-2.34) more likely than nulliparous
women to use LARC.
Results of the sensitivity analysis on the subset popula-
tion of women employees were very similar to the results
described above (Table 2). In the sensitivity analysis using
a 30 days of supply threshold to identify SARC users, the
results were consistent (data not shown).
Influence of age groups and time periods over LARC use
Figure 3 shows the odds ratios (95 % CI) of using
LARC for age group and time period interaction terms.
Across all age groups, women in the most recent period
(i.e., 2013–2014) had a higher likelihood of using LARC
as opposed to women of the same age in more recent
periods (i.e., 1999–2000, 2001–2006, and 2006–2012).
The increase in LARC use was especially pronounced
in young women. Compared to women aged 18–24 in
2001-2006, women aged 18–24 in 2006-2012 and in
2013-2014 were respectively 6.4-fold (95%CI: 5.91-6.86)
and 14.7-fold (95%CI: 13.59-15.89) more likely to use
LARC over SARC methods.
Discussion
This large retrospective study based on commercial
healthcare claims data found that the use of LARC
methods among US women seeking contraception
increased between January 1999 and March 2014.
Moreover, the observation held for all age groups
among women of childbearing age (15–44 years old)
and also suggested that the introduction of new LARC
Fig. 1 Contraceptive users’ disposition. LARC: Long Acting Reversible Contraceptive, SARC: Short Acting Reversible Contraceptive. Note: 1. A
SARC episode was defined as SARC claims totaling 60 days of supply or more in a given 6-month period
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Table 1 Baseline Characteristics of Women Using SARC or LARC Method Stratified by Time Perioda

















Age at index date, mean ± SD [median] 32.5 ± 6.4 [34] 30.0 ± 7.7 [30] 32.8 ± 5.9 [33] 28.8 ± 8.0 [29] 31.4 ± 7.2 [32] 27.4 ± 8.1 [26] 30.3 ± 7.7 [31] 27.2 ± 7.8 [25]
Age categories, N (%)
15–17 years 1 (1.1 %) 564 (3.3 %) 23 (0.4 %) 12,799 (5.9 %) 1,106 (2.2 %) 45,554 (9.6 %) 484 (2.7 %) 14,066 (6.6 %)
18–24 years 13 (13.8 %) 4,385 (25.6 %) 549 (8.6 %) 65,033 (29.8 %) 8,723 (17.5 %) 156,526 (33.0 %) 4,809 (26.4 %) 85,938 (40.1 %)
25–34 years 42 (44.7 %) 6,771 (39.6 %) 3,220 (50.5 %) 79,990 (36.6 %) 21,846 (43.8 %) 163,430 (34.5 %) 6,838 (37.5 %) 69,339 (32.4 %)
35–44 years 38 (40.4 %) 5,400 (31.5 %) 2,587 (40.6 %) 60,493 (27.7 %) 18,228 (36.5 %) 108,599 (22.9 %) 6,111 (33.5 %) 44,936 (21.0 %)
Region, N (%)
South 29 (30.9 %) 8,584 (50.1 %) 2,502 (39.2 %) 86,066 (39.4 %) 16,687 (33.4 %) 149,431 (31.5 %) 5,561 (30.5 %) 58,042 (27.1 %)
Northeast 13 (13.8 %) 2,443 (14.3 %) 899 (14.1 %) 52,203 (23.9 %) 7,474 (15.0 %) 107,570 (22.7 %) 4,520 (24.8 %) 58,460 (27.3 %)
Midwest 29 (30.9 %) 4,342 (25.4 %) 1,008 (15.8 %) 43,311 (19.8 %) 10,099 (20.2 %) 109,389 (23.1 %) 4,256 (23.3 %) 53,605 (25.0 %)
West
Unknown region 0 (0.0 %) 8 (0.0 %) 93 (1.5 %) 3,299 (1.5 %) 4,267 (8.6 %) 24,237 (5.1 %) 351 (1.9 %) 13,757 (6.4 %)
Employment status, N (%)
Employee
Employee 47 (50.0 %) 8,683 (50.7 %) 1,965 (30.8 %) 80,723 (37.0 %) 17,459 (35.0 %) 167,890 (35.4 %) 5,660 (31.0 %) 59,576 (27.8 %)
Retiree 0 (0.0 %) 4 (0.0 %) 63 (1.0 %) 1,990 (0.9 %) 627 (1.3 %) 6,610 (1.4 %) 185 (1.0 %) 2,067 (1.0 %)
Other employee status 5 (5.3 %) 116 (0.7 %) 428 (6.7 %) 6,881 (3.2 %) 3,208 (6.4 %) 12,673 (2.7 %) 1,376 (7.5 %) 10,775 (5.0 %)
Dependant
Spouse 34 (36.2 %) 4,199 (24.5 %) 3,639 (57.0 %) 62,712 (28.7 %) 20,366 (40.8 %) 105,241 (22.2 %) 5,278 (28.9 %) 34,503 (16.1 %)
Child 8 (8.5 %) 4,042 (23.6 %) 263 (4.1 %) 64,181 (29.4 %) 8,092 (16.2 %) 179,287 (37.8 %) 5,682 (31.1 %) 106,449 (49.7 %)
Other type of dependant 0 (0.0 %) 73 (0.4 %) 14 (0.2 %) 1,615 (0.7 %) 131 (0.3 %) 2,197 (0.5 %) 52 (0.3 %) 803 (0.4 %)
Unknown employee/dependant status 0 (0.0 %) 3 (0.0 %) 7 (0.1 %) 213 (0.1 %) 20 (0.0 %) 211 (0.0 %) 9 (0.0 %) 106 (0.0 %)
Plan type, N (%)
Point of Service (POS) 26 (27.7 %) 6,040 (35.3 %) 2,561 (40.1 %) 87,078 (39.9 %) 30,094 (60.3 %) 284,798 (60.1 %) 11,289 (61.9 %) 137,026 (63.9 %)
Preferred Provider Organization (PPO) 32 (34.0 %) 5,837 (34.1 %) 1,922 (30.1 %) 69,951 (32.0 %) 7,059 (14.1 %) 76,131 (16.1 %) 2,959 (16.2 %) 32,516 (15.2 %)
Health Maintenance Organization (HMO) 8 (8.5 %) 1,099 (6.4 %) 912 (14.3 %) 30,219 (13.8 %) 5,871 (11.8 %) 55,814 (11.8 %) 1,479 (8.1 %) 19,302 (9.0 %)
Indemnity 9 (9.6 %) 1,298 (7.6 %) 231 (3.6 %) 12,744 (5.8 %) 3,212 (6.4 %) 28,194 (5.9 %) 1,334 (7.3 %) 17,682 (8.3 %)











Table 1 Baseline Characteristics of Women Using SARC or LARC Method Stratified by Time Perioda (Continued)
Available information on wage and type of
industry, N (%)
33 (35.1 %) 6,534 (38.2 %) 2,108 (33.0 %) 78,405 (35.9 %) 18,990 (38.1 %) 170,724 (36.0 %) 6,731 (36.9 %) 65,991 (30.8 %)


















Type of industry, N (%)
Technology 5 (15.2 %) 2,290 (35.0 %) 218 (10.3 %) 25,574 (32.6 %) 2,774 (14.6 %) 27,472 (16.1 %) 612 (9.1 %) 5,872 (8.9 %)
Transportation 3 (9.1 %) 544 (8.3 %) 270 (12.8 %) 7,753 (9.9 %) 2,975 (15.7 %) 16,368 (9.6 %) 812 (12.1 %) 6,161 (9.3 %)
Financial 9 (27.3 %) 1,835 (28.1 %) 188 (8.9 %) 17,789 (22.7 %) 2,009 (10.6 %) 25,725 (15.1 %) 1,558 (23.1 %) 14,605 (22.1 %)
Manufacture 10 (30.3 %) 1,480 (22.7 %) 141 (6.7 %) 6,238 (8.0 %) 1,169 (6.2 %) 10,319 (6.0 %) 389 (5.8 %) 4,179 (6.3 %)
Consumer 6 (18.2 %) 385 (5.9 %) 62 (2.9 %) 6,181 (7.9 %) 2,689 (14.2 %) 28,510 (16.7 %) 572 (8.5 %) 9,661 (14.6 %)
Government 0 (0.0 %) 0 (0.0 %) 193 (9.2 %) 3,216 (4.1 %) 2,941 (15.5 %) 18,085 (10.6 %) 952 (14.1 %) 8,362 (12.7 %)
Healthcare 0 (0.0 %) 0 (0.0 %) 143 (6.8 %) 5,729 (7.3 %) 829 (4.4 %) 9,502 (5.6 %) 253 (3.8 %) 2,315 (3.5 %)
Other 0 (0.0 %) 0 (0.0 %) 893 (42.4 %) 5,925 (7.6 %) 3,604 (19.0 %) 34,743 (20.4 %) 1,583 (23.5 %) 14,836 (22.5 %)
Comorbidities, N (%)
Asthma 1 (1.1 %) 498 (2.9 %) 271 (4.2 %) 7,726 (3.5 %) 2,399 (4.8 %) 20,858 (4.4 %) 924 (5.1 %) 10,684 (5.0 %)
Hypothyroidism 1 (1.1 %) 362 (2.1 %) 339 (5.3 %) 6,491 (3.0 %) 2,633 (5.3 %) 16,640 (3.5 %) 917 (5.0 %) 8,616 (4.0 %)
Hypertension 4 (4.3 %) 309 (1.8 %) 341 (5.3 %) 4,663 (2.1 %) 2,568 (5.1 %) 12,099 (2.6 %) 850 (4.7 %) 5,515 (2.6 %)
Diabetes 3 (3.2 %) 136 (0.8 %) 113 (1.8 %) 2,283 (1.0 %) 936 (1.9 %) 5,775 (1.2 %) 323 (1.8 %) 2,609 (1.2 %)
Obesity 0 (0.0 %) 132 (0.8 %) 120 (1.9 %) 2,511 (1.2 %) 1,899 (3.8 %) 8,900 (1.9 %) 921 (5.0 %) 5,445 (2.5 %)
Inflammatory bowel disease 0 (0.0 %) 59 (0.3 %) 22 (0.3 %) 882 (0.4 %) 257 (0.5 %) 2,129 (0.4 %) 124 (0.7 %) 1,217 (0.6 %)
Epilepsy 1 (1.1 %) 57 (0.3 %) 66 (1.0 %) 857 (0.4 %) 533 (1.1 %) 2,538 (0.5 %) 220 (1.2 %) 1,446 (0.7 %)
Rheumatoid arthritis 0 (0.0 %) 47 (0.3 %) 30 (0.5 %) 659 (0.3 %) 218 (0.4 %) 1,741 (0.4 %) 107 (0.6 %) 954 (0.4 %)
Venous thromboembolism 1 (1.1 %) 20 (0.1 %) 58 (0.9 %) 293 (0.1 %) 411 (0.8 %) 681 (0.1 %) 142 (0.8 %) 300 (0.1 %)
Systemic lupus erythematosus 0 (0.0 %) 19 (0.1 %) 18 (0.3 %) 297 (0.1 %) 174 (0.3 %) 704 (0.1 %) 43 (0.2 %) 326 (0.2 %)
Patients switching contraception methodb,
N (%)
3 (3.2 %) 13 (0.1 %) 532 (8.3 %) 2,357 (1.1 %) 5,404 (10.8 %) 17,501 (3.7 %) 1,284 (7.0 %) 3,948 (1.8)
Gynaecology historyc, N (%)
History of SARC use 23 (24.5 %) 11,542 (67.4 %) 2,225 (34.9 %) 138,290 (63.3 %) 15,857 (31.8 %) 309,903 (65.4 %) 5,753 (31.5 %) 172,756 (80.6 %)
History of LARC use 1 (1.1 %) 15 (0.1 %) 187 (2.9 %) 541 (0.2 %) 2,355 (4.7 %) 4,006 (0.8 %) 1,472 (8.1 %) 2,760 (1.3 %)
History of obstetrician/gynaecologist
visits
80 (85.1 %) 9,339 (54.6 %) 5,875 (92.1 %) 138,829 (63.6 %) 44,833 (89.8 %) 303,585 (64.0 %) 15,684 (86.0 %) 140,701 (65.7 %)
Pregnancy history 44 (46.8 %) 1,671 (9.8 %) 3,182 (49.9 %) 25,803 (11.8 %) 21,556 (43.2 %) 49,069 (10.3 %) 5,895 (32.3 %) 16,885 (7.9 %)











Table 1 Baseline Characteristics of Women Using SARC or LARC Method Stratified by Time Perioda (Continued)
Nulliparous status, N (%)
Nulliparous 21 (22.3 %) 10,116 (59.1 %) 903 (14.2 %) 131,780 (60.4 %) 14,571 (29.2 %) 319,441 (67.4 %) 8,136 (44.6 %) 158,741 (74.1 %)
Non-nulliparous 73 (77.7 %) 6,928 (40.5 %) 5,455 (85.5 %) 84,707 (38.8 %) 35,181 (70.5 %) 152,260 (32.1 %) 10,045 (55.1 %) 54,629 (25.5 %)
Unknown nulliparous status 0 (0.0 %) 76 (0.4 %) 21 (0.3 %) 1,828 (0.8 %) 151 (0.3 %) 2,408 (0.5 %) 61 (0.3 %) 909 (0.4 %)
aBaseline characteristics of patients with either a LARC claim or claims totaling 60 days of supply of SARC. The 12-month period before the first SARC or LARC claims for each patient in each time period was used to
calculate the characteristics
bPatients switching from a SARC to a LARC or from a LARC to a SARC during the time period where the characteristics were evaluated











products and consequently the potential fulfillment of
women’s unmet contraceptive needs, could be an
important driver of LARC use. The current study has
the advantage of relying on a large sample of women
insured through their employer. These employers, part
of the Fortune 500 ranking, are likely to offer advanta-
geous health plan coverage and to cover most contra-
ceptives including LARCs. This study thus suggests
that maintaining an open-access to all products and
providing more options within the LARC category
could enable more women to choose a LARC over a
SARC method.
The statistically significant increase in LARC use since
2002 reported in this study concurs with the results of
the recent US National Survey of Family Growth (NSFG)
that reported that LARC use among all women 15–44
years old had increased from 1.5 % in 2002 to 7.2 % in
the period 2011–2013 [9]. Another analysis of the 2002
and 2006–2010 NSFG data previously demonstrated that
the proportion of LARC users among all contraceptive
users had grown from 2.4 % in 2002 up to 8.5 % in 2009
[11]. One of the reasons for this evolution may be a shift
in reproductive health expert opinions and recommen-
dations regarding LARCs. IUDs in particular were trad-
itionally seen as appropriate for parous women only, in
part owing to label recommendations to that effect
which were initially present for ParaGard and Mirena,
the only two IUDs on the market in the US for quite
some time following the Dalkon shield debacle. The
recommendation remains for Mirena but was removed
from ParaGard labeling in 2005 [15]. Skyla and Liletta,
approved by the US food and drug administration (FDA)
in 2013 and 2015, respectively, included nulliparous sub-
jects in the registration clinical trials and consequently
do not contain such a recommendation; rather, the la-
beling specifies that they are indicated for prevention of
pregnancy without reference to any particular popula-
tion [16, 17]. The former is included in the time frame
of this study while the latter is not due to its very re-
cent approval.
Contrary to the past perceptions and opinions, LARC
methods are safe for nulliparous young women, do not
cause tubal infertility, and studies report a rapid return
to fertility after removal [18–20]. Consequently, experts
have been increasingly advocating for use of LARC
methods prior to childbearing [21–23]. Hence the Ameri-
can Congress of Obstetricians and Gynecologists recom-
mended IUDs as first-line contraception as early as 2005,
for users including teenagers and younger women, and
the American Academy of Pediatrics has recently promul-
gated the same recommendation [21, 22]. More recently,
the Centers for Disease Control and prevention reported
that IUDs were safe and effective in nulliparous women
[23].
However, there are still several obstacles hindering
LARC use. One of them is perceived high costs [13, 14],
although it has been proven that LARC methods are
highly cost-effective when used for as little as the
shortest available duration of three years [24, 25]. The
Affordable Care Act (ACA) of 2010 that imposes on
most healthcare plans to cover the full range of contra-
ceptive methods as of August 2012, including LARC,
with no patient cost-sharing, could weaken this barrier
[11]. Unfortunately, for many plans, the requirement
Fig. 2 Progression of LARC use over time among LARC and SARC users. * Denotes statistical significance (P < 0.05) compared to the previous year
using a Pearson chi-squared test. LARC: Long Acting Reversible Contraceptive, SARC: Short Acting Reversible Contraceptive
Law et al. Reproductive Health  (2016) 13:96 Page 8 of 12
Table 2 Predictors of LARC use among women using SARC or LARC
Odds Ratioa (95 % CI)
All Women (N = 732,430) All Employeesb (N = 249,021)
Time Period
Jan 1999–Dec 2000 0.28 (0.24 - 0.33)* 0.24 (0.18 - 0.33)*
Jan 2001–Jun 2006 1.00 1.00
Jul 2006–Dec 2012 3.66 (3.57 - 3.74)* 3.63 (3.47 - 3.80)*
Jan 2013–Mar 2014 6.61 (6.43 - 6.80)* 6.73 (6.37 - 7.10)*
Age group
15–17 year old 0.55 (0.53 - 0.58)* -
18–24 year old 1.00 1.00
25–34 year old 1.03 (1.00 - 1.05)* 1.29 (1.22 - 1.37)*
35–44 year old 1.21 (1.18 - 1.24)* 1.63 (1.54 - 1.73)*
Region
South 1.00 1.00
Northeast 0.80 (0.79 - 0.82)* 0.88 (0.84 - 0.92)*
Midwest 0.90 (0.88 - 0.92)* 0.97 (0.93 - 1.00)
West 1.27 (1.24 - 1.30)* 1.29 (1.24 - 1.34)*
Unknown region 1.39 (1.35 - 1.44)* 1.20 (1.12 - 1.29)*
Plan type
Point of Service (POS) 1.00 1.00
Preferred Provider Organization (PPO) 0.98 (0.95 - 1.01) 0.89 (0.85 - 0.94)*
Health Maintenance Organization (HMO) 1.05 (1.03 - 1.08)* 0.93 (0.90 - 0.97)*
Indemnity 1.14 (1.10 - 1.18)* 1.04 (0.98 - 1.12)
Unknown plan type 1.21 (1.17 - 1.25)* 1.31 (1.23 - 1.38)*
Type of industry
Technology - 1.00
Transportation - 1.44 (1.36 - 1.52)*
Financial - 0.93 (0.88 - 0.98)*
Manufacture - 1.07 (1.00 - 1.14)*
Consumer - 1.07 (1.01 - 1.13)*
Government - 1.57 (1.47 - 1.67)*
Healthcare - 0.81 (0.75 - 0.87)*
Other - 1.07 (1.02 - 1.12)*
Wage (per 100,000 2014 US$) - 0.94 (0.90 - 0.98)*
Comorbidities
Venous thromboembolism 13.50 (6.82 - 26.72)* 22.12 (7.77 - 62.93)*
Systemic lupus erythematosus 1.90 (1.58 - 2.28)* 1.92 (1.42 - 2.59)*
Epilepsy 1.92 (1.02 - 3.60)* 1.39 (0.45 - 4.31)
Hypertension 1.55 (1.48 - 1.63)* 1.63 (1.51 - 1.75)*
Obesity 1.54 (1.46 - 1.64)* 1.64 (1.50 - 1.79)*
Asthma 1.25 (1.19 - 1.31)* 1.30 (1.19 - 1.41)*
Diabetes 1.17 (1.09 - 1.26)* 1.21 (1.08 - 1.36)*
Rheumatoid arthritis 1.19 (1.04 - 1.35)* 1.22 (0.97 - 1.54)
Inflammatory bowel disease 1.09 (0.95 - 1.24) 1.17 (0.94 - 1.45)
Hypothyroidism 1.05 (1.00 - 1.10)* 1.12 (1.04 - 1.21)*
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only took effect in 2013; furthermore, many exemptions
relative to contraception coverage were granted; and fi-
nally, a 2014 ruling of the U.S. Supreme Court allowed
closely held, for-profit firms to opt out of the contra-
ceptive coverage mandate in the ACA [26]. In relation
to the ACA, the Guttmacher Institute reported that
several plans currently cover prescription contraceptive
drugs but not devices [26]. The impact of the ACA on
promoting LARC adoption remains therefore unclear,
and it is specifically difficult to control for such an
event given that its implementation has been made over
such a long time span. Another barrier to increasing
LARC use is lingering myths and misconceptions about
LARC and contraception, at both the user and provider
level [27, 28]. Russo et al. [29] recently reviewed and
attempted to debunk such misconceptions (e.g., IUDs
Table 2 Predictors of LARC use among women using SARC or LARC (Continued)
Gynecology history
History of SARC use 0.08 (0.08 - 0.08)* 0.07 (0.07 - 0.07)*
History of LARC use 254.14 (248.85 - 259.55)* 310.20 (297.55 - 323.39)*
History of obstetrician/gynecologist visits 1.75 (1.72 - 1.78)* 1.79 (1.74 - 1.85)*
Pregnancy history 2.80 (2.74 - 2.85)* 2.32 (2.24 - 2.41)*
Abortion history 0.98 (0.94 - 1.01) 0.93 (0.87 - 1.00)*
Nulliparous status
Nulliparous 1.00 1.00
Non nulliparous 2.29 (2.24 - 2.34)* 2.56 (2.48 - 2.64)*
Unknown nulliparous status 1.30 (1.15 - 1.47)* -
aOdds ratios and confidence intervals were obtained using a generalized estimating equation model controlling for all variables listed and adjusting for repeated
measurements among patients
bWomen aged 18 or more with employee status and for whom wage was known were considered for this analysis
*Denotes statistical significance compared to the reference (P<0.05)
Fig. 3 Likelihood of Using LARC (over SARC) Across Time Periods and Age Groups [1]. * Denotes statistical significance (P < 0.05) compared to the
reference group of women 18–24 years old using LARC in the period January 2001 – June 2006. LARC: Long Acting Reversible Contraceptive, SARC:
Short Acting Reversible Contraceptive. Note: The following covariates were also included in the model: region, plan type, comorbidities (i.e., venous
thromboembolism, systemic lupus erythematosus, epilepsy, hypertension, obesity, asthma, diabetes, rheumatoid arthritis inflammatory bowel disease,
and hypothyroidism), history of SARC use, history of LARC use, history of obstetrician/gynecologist visits, pregnancy history, abortion history, and
nulliparous status
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cause pelvic inflammatory disease) in their 2013 stud.
Meanwhile, it was also found in a 2012 study that patients
overestimated SARC method efficacy [30]. Therefore,
there is still a need to better educate women and providers
on contraception methods and LARC in particular.
Broadening the choice of LARC methods could also
help increase LARC use, and potentially contribute to
changing the perceptions of women and healthcare
providers about them. Indeed, bringing to market new
devices could help increase the visibility of LARC
methods by generating promotional activity from the
manufacturer which in turn can raise awareness
among both consumers and providers, and by increasing
the research interest for LARC, further contributing to an
increased knowledge around that class of contraceptives.
Diversifying LARC options could also help address the
variety of needs of women seeking mid-to-long term
reversible contraception [31]. This is supported by the
results of the present study, which showed that periods
following introduction of newer LARC methods were one
of the main drivers of LARC use.
The present study also showed an acceleration of
LARC adoption among younger women since availability
of Skyla in 2013. Notably, women from the 18–24 age
group were 14.7-fold more likely to use a LARC method
compared to women of the same age group in 2001-
2006. In addtition, that likelihood was also higher than
that of women from the 25–34 and 35–44 age groups
compared to the same 18–24 age group in 2001–2006
(respectively 11.03 and 13.08). This could be related to
the change in reproductive health specialists’ opinions
and recommendations regarding the suitability of
LARCs for younger women already discussed previously
[22, 32, 33], but also, as pointed above, to the availability
of new LARC products that better address the needs of
younger and nulliparous women.
Results of the present study also showed that among
common comorbidities associated with childbearing
age, VTE history was a strong predictor of LARC use
(estimated likelihood of LARC use after a VTE episode
was 13.5). As oral contraceptives, are associated with
an increased risk of VTE [34], and as some LARC
methods, such as Mirena, decrease or can stop men-
strual bleeding, they can be a safer option for VTE pa-
tients who have to be treated with blood thinning
medication, and for whom pregnancy is a risk factor for
VTE (VTE being the leading cause of maternal death in
the US) [35]. More generally, LARC methods increase and
enhance the spectrum of contraceptive options in women
with medical conditions (e.g., systemic lupus erythemato-
sus), either to more efficiently prevent pregnancy or be-
cause the condition treatment would interfere with
traditional contraception (e.g., epileptic treatment interfer-
ing with hormonal pills) [36].
Limitations
This study is subject to certain limitations. First, even
though an algorithm was developed to capture the end
of a LARC episode, all removal of LARC methods may
not have been captured. Second, claims databases may
contain inaccuracies or omissions in procedures, diag-
noses, or costs, and no information was provided as to
whether or not medication was taken as prescribed.
Third, contraceptives purchased over-the-counter were
not available in the database, which may have resulted
in an underestimation of SARC use. Fourth, even
though the Optum Health Reporting and Insights data-
base can be generalized to the large subgroup of the
employed US population, our study population con-
sisted of privately-insured individuals, and, therefore,
our results might not be generalizable to the entire
population of contraceptive users of which an import-
ant proportion is uninsured or publicly-insured. Fifth, it
is difficult to ignore the influence of the growing famil-
iarity of the public with LARC on LARC adoption, or
assess whether this growth would have happened at all
without the introduction of new LARC methods that
fulfills women’s unmet contraceptive needs. Nonethe-
less, we think both factors played an important role in
the increasing popularity of the use of LARC. Finally,
public discussions of benefits and risks of the different
contraceptives (or other events such as changes in
health insurance coverage and re-imbursement rules or
in perception of the suitability of IUDs for nulliparous
or younger women) may influence the prescription of
LARC and SARC methods; however, time periods asso-
ciated with these discussions and events were not con-
sidered as specific covariates in the statistical models
used in this study. These factors may have been cap-
tured nonetheless in the time trend that was included
as a covariate in the study.
Conclusions
This study found that privately insured women of child-
bearing age seeking contraception increasingly turned to-
wards LARC methods over SARC methods from 1999 to
2014. It also found that one of the main associations of
this trend was the availability of newer, more diversified,
LARC methods, and that the rising trend in LARC use
was particularly pronounced among younger women.
With the still preoccupyingly high rate of unintended
pregnancies in the US, the high costs associated with
unintended pregnancies, and the difficulties often faced by
women seeking abortion, this study supports the possibil-
ity that a sustained effort in broadening the range of avail-
able LARC methods may facilitate their adoption. Future
research is needed to assess LARC use in uninsured or
publicly-insured populations.
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